If the average orphan drug price is now $200k , and Trof 1) is...

If the average orphan drug price is now $200k , and Trof 1) is the only approved treatment for Retts, 2) produces a robust improvement and 3) treats a disease with a very high burden (which is true for Retts) then logically the price for Trof should be at the upper end of the range. Acadia's first obligation is to maximise its return for shareholders, which means they should be pricing at the maximum the market can bear (i.e. maximising penetration times price).

Based on the information we have its hard to see how the price will end up lower than $200k, let alone the $50k to $100k some are suggesting.

This information suggests to me a price well over $200k. i.e. $250k seems far more likely to me than $150k.